In late 2013, new direct acting antivirals (DAAs) for the treatment of hepatitis C were launched worldwide. These new treatment regimens, simpler, shorter and capable of curing over 90% of people with HCV offer the perspective of making hepatitis C rare/eliminated. However, the price of those new regimens remains the main barrier to access to the 80 millions of chronically infected people worldwide[1].

Médecins du Monde (MdM) and Treatment Action Group (TAG) developed the project mapCrowd.org, an online crowdsourcing platform designed to help collect and share up-to-date HCV information: http://mapcrowd.org/

To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org.

In addition, please find here attached the 2 press releases from MdM ES and MdM FR (click here for the english version)

 

 

Advertisements